Local
Ambrosia Biosciences Announces the Nonclinical Data Profiles of Two Oral Small Molecule Programs: A GLP-1 Receptor Agonist Intended for Once-Weekly Dosing and a GIP Receptor Antagonist
Meet in Common connects news with real conversations. Use ThinkMatch to arrange a Roundtable and meet people to discuss this story.
Source: The Desert Review

AMB-895 and AMB-131 demonstrate highly differentiated PK profiles and robust efficacy in preclinical models
This excerpt comes from the named source. Read the original for the full reporting.
Read the original at The Desert Review


